SJIA remains a very complex, heterogeneous, difficult-to-treat condition in many patients, particularly those with long-lasting systemic disease and/or erosive polyarthritis, who do not respond well to Il-1 and Il-6 antagonists, and those with remitting–relapsing MAS. The gene discussed is IL6; the disease is macrophage activation syndrome.